RMD Stock Overview
Develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
ResMed Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$237.27 |
| 52 Week High | US$260.49 |
| 52 Week Low | US$164.12 |
| Beta | 0.68 |
| 1 Month Change | -2.67% |
| 3 Month Change | -3.62% |
| 1 Year Change | 38.43% |
| 3 Year Change | -8.33% |
| 5 Year Change | 51.90% |
| Change since IPO | 35,214.60% |
Recent News & Updates
ResMed: Solid Execution, Pricey Valuation
Nov 25Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why
Nov 13
Recent updates
ResMed: Solid Execution, Pricey Valuation
Nov 25Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why
Nov 13We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease
Nov 01Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Oct 20ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price
Oct 08Why ResMed's Rally Is Just Getting Started
Sep 18ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors
Sep 13ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53
Aug 05Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?
Jul 29Returns On Capital Are A Standout For ResMed (NYSE:RMD)
Jul 15ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating
Jul 03An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued
Jul 02ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 30ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear
Apr 18With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case
Mar 22Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future
Mar 10An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued
Feb 12Why ResMed Is One Of My Top Picks In 2024
Jan 22A First Look At ResMed
Jan 09ResMed: Weight-Loss Drug Worries Provide Buying Opportunity
Oct 28ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity
Sep 12ResMed Has Become A Steal (Rating Upgrade)
Aug 10Compound Your Wealth With ResMed
Jul 04Shareholder Returns
| RMD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -0.5% | -1.5% | -2.4% |
| 1Y | 38.4% | 10.1% | 23.3% |
Return vs Industry: RMD exceeded the US Medical Equipment industry which returned 10.1% over the past year.
Return vs Market: RMD exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| RMD volatility | |
|---|---|
| RMD Average Weekly Movement | 3.9% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RMD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RMD's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 9,980 | Mick Farrell | www.resmed.com |
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
ResMed Inc. Fundamentals Summary
| RMD fundamental statistics | |
|---|---|
| Market cap | US$34.82b |
| Earnings (TTM) | US$1.11b |
| Revenue (TTM) | US$4.81b |
31.3x
P/E Ratio7.2x
P/S RatioIs RMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RMD income statement (TTM) | |
|---|---|
| Revenue | US$4.81b |
| Cost of Revenue | US$2.00b |
| Gross Profit | US$2.80b |
| Other Expenses | US$1.69b |
| Earnings | US$1.11b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.58 |
| Gross Margin | 58.33% |
| Net Profit Margin | 23.15% |
| Debt/Equity Ratio | 13.0% |
How did RMD perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield26%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:53 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ResMed Inc. is covered by 56 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | ANZ Equities Pty Limited |
| Russell Wright | APP Securities Pty Ltd. |
| David Rescott | Baird |